A regulatory protein in astrocytes may explain how certain memories persist over time for learning and cognitive function.

New perfusion technologies and AI-driven controls are accelerating adoption across commercial biologics manufacturing.

Fast, local cryopreservation is a consistent bottleneck for autologous cell therapy developers, even in major cell and gene therapy hubs.

USP’s Diane McCarthy on the emerging standards platform and opportunities for stakeholders to help shape standards evolution.

Novartis has agreed to acquire Myricx Bio, a London-based developer of next-generation antibody-drug conjugates (ADCs), for ...

To test this strategy, the team engineered protein immunogens that mimic key HIV envelope structures known to initiate bnAb ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...

Researchers say ability to see for the first time previously hidden indicators of MS disease progression is an important advance.

Researchers have developed new AI approach to select chemical compounds potentially effective for treating tuburculosis.

By restoring the body’s ability to produce KLK1, therapies are emerging for preeclampsia moms and for acute ischemic stroke who missed the tPA window.

PROTACs have helped redefine what may be possible in drug discovery. By harnessing the ubiquitin-proteasome system to ...